drugset

drugset / Trial / NCT00514696

Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia

NCT00514696 ↗

Phase 2 Completed 12 enrolled La Jolla Pharmaceutical Company

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of GCS-100 and the biologic activity of GCS-100 in subjects with chronic lymphocytic leukemia.

Timeline

Start: 2007-02
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GCS-100	Unknown	160 mg/m2	Intravenous

Indications